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The mechanisms that guide the development of mucosal-associated innate lymphoid cells (ILCs) producing
IL-17, IL-22, and IFN-g are the subject of intense interest. In this issue of Immunity, Hughes et al. (2010) iden-
tify a new role for IL-1b in regulating an IL-22-producing ILC.Lymphoid tissues associated with
mucosal surfaces harbor an elaborate
immune defense system that plays
a primary role in protection against
invading pathogens. Developmentally
related innate lymphoid cells (ILCs),
including lymphoid tissue inducer (LTi)
cells, IL-22-producing cells expressing
natural cytotoxicity receptors (NK22,
NCR22, and NKR-LTi), and classical NK
cells have been identified in mucosal-
associated lymphoid tissues (MALT) in
both man and mouse (Colonna, 2009).
These diverse ILCs produce a variety of
cytokines (IL-17, IL-22, and IFN-g) that
are implicated in protection against infec-
tion. In addition, these cytokines influence
tissue remodeling after stress or inflam-
mation and, when deregulated, can lead
to serious disease, including autoimmu-
nity and cancer exacerbation. Accord-
ingly, it is essential to understand the
mechanisms that control the generation
of these innate lymphocytes and that
regulate their function. Hughes et al.
(2010) provide an important advance by
demonstrating that the IL-1R1 can be
used to identify human ILCs within
secondary lymphoid tissue (SLT) that
have strong IL-22-producing capacity.
Moreover, they provide evidence sug-
gesting that IL-1b, derived from dendritic
cells (DCs), can modulate the fate of
developing ILCs atmucosal sites, favoring
the production of IL-22+ ILC while inhi-
biting generation of classical IFN-g+ NK
cells. These findings suggest a mecha-
nistic solution for ILC diversification and,
along with a recent report (Cella et al.,
2010), demonstrate that regulation of
IL-1b expression may fine-tune the func-
tional activities of mucosal-associated
ILCs under diverse conditions.734 Immunity 32, June 25, 2010 ª2010 ElsevIL-17, IL-22, and IFN-g have essential
roles in protecting mucosal surfaces
from pathogen invasion. Among the ILC
that produce these cytokines, LTi cells
(that play a nonredundant role in lymphoid
tissue organogenesis) as well as classical
NK cells can be considered as innate
‘‘versions’’ of the adaptive Th17 and Th1
cells, respectively. Recently, a human
ILC with properties of both LTi and NK
cells was described. Dubbed ‘‘NK22’’
(Cella et al., 2009) or RORC+CD127+ NK-
like cells (Cupedo et al., 2009), these cells
have LTi (RORC, LTA, LTB, and CCR6)
and NK cell (CD56, NKp46, and NKp44)
features. In the fetus, these cells produce
mainly IL-17, whereas postnatal cells
show strong IL-22 production, suggesting
that these cells could represent innate
Th17 cell-like and Th22 cell-like subsets,
respectively. RORC+CD127+ NK-like cells
could be derived after culture of human
fetal or postnatal LTi cells in IL-2, suggest-
ing a precursor-product relationship.
These cultures also contained cells
bearing NK markers (NKp30 and NKp44)
and low amounts of granzyme B and
IFN-g, leading to the initial conclusion
that human LTi cells were IL-15-respon-
sive NK cell precursors (Cupedo et al.,
2009). This notion was not unheralded,
given that Mebius and colleagues had
shown that fetal mouse LTi cells could
generate lytic NK1.1+ NK cells (and DC
cells) after in vitro culture (Mebius et al.,
1997). Still, both NK22 cells as well as
RORC+CD127+ NK-like cells isolated ex
vivo or generated in vitro were clearly
phenotypically and functionally different
from classical NK cells, lacking expres-
sion of killer cell Ig-like receptors (KIRs)
and perforin (Cella et al., 2009; Cupedo
et al., 2009). Thus, the developmentalier Inc.relationships and frontiers between
human LTi, NK22, RORC+CD127+, and
classical NK cells remained fuzzy.
The Caligiuri lab has proposed a five-
stage model for human NK cell develop-
ment in SLT on the basis of expression
of CD34, CD117, and CD94 (Freud et al.,
2006). In this scheme, immature NK cells
(stage 3 iNK: CD34CD117+CD94)
harbored NK cell but not T cell, B cell, or
DC precursors. Interestingly, a subset of
stage 3 cells expressed IL-22 and the
transcription factor AHR that is required
for inducible IL-22 expression, but lacked
phenotypic and functional attributes of
mature NK cells (Hughes et al., 2009).
The collective observations were there-
fore consistent with a model in which
immature NK cells could have a dual func-
tion, being precursors to mature NK cells
but also providing a potential source of
IL-22 in SLT that could impact onmucosal
immune responses and help sustain
tissue integrity during infection or inflam-
mation (Figure 1).
Although this ‘‘dual function’’ iNK cell
model was attractive, an alternative
model in which stage 3 iNK cells
comprised several distinct lymphoid cell
precursors needed to be considered,
given that only a minor fraction of stage
3 iNK cells gave rise to bona fide NK cells
after in vitro culture. In this case, true NK
cell precursors would be distinct from IL-
22+ cells, with the latter possibly repre-
senting NK22, RORC+CD127+ cells or
related ILCs or their precursors (Figure 1).
Hughes et al. (2010) now provide further
evidence for heterogeneity within stage 3
cells by identifying a subset of cells
expressing the interleukin-1 receptor one
(IL-1R1). By separating and analyzing IL-
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Figure 1. Models for Development of IL-22-Producing Innate Lymphoid Cells versus
Classical NK Cells in Secondary Lymphoid Tissues and Mucosal Associated Lymphoid
Tissue
‘‘Dual function’’ model (left) proposes that developing cells pass through an IL-22+ stage that can be
expanded through IL-1b from dendritic cells (DCs). Further maturation of IL-22+ cells to lytic IFN-g+ NK
cells is inhibited by IL-1b but promoted by IL-15. ‘‘Dual precursor’’ model (right) proposes distinct dedi-
cated precursors for IL-22+ ILC and classical NK cells that are driven by IL-1b and IL-15, respectively.
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was restricted to the IL-1R1hi subset;
this subset concomitantly expressed
CD127, CD161, LTA, and CCR7 (LTi cell-
like features) but also CD56 and NKp44,
suggesting that they were closely related
to the previously described NK22 and
RORC+CD127+ cells. In contrast, the
IL-1R1lo subset (representing 20% of
stage 3 cells) lacked expression of these
markers.
Hughes et al. (2010) then assess the
impact of exogenous IL-1b on the devel-
opment of NK cells from stage 3 iNK cells.
As expected, only the IL-1R1hi subset re-
sponded to IL-1b, which enhanced cell
proliferation in the presence of IL-15 re-
sulting in higher overall cell yields. IL-1b
in the absence of IL-15, however, wasnot sufficient for growth. Interestingly, IL-
1b+IL-15 clearly sustained IL-22 expres-
sion in IL-1R1hi cells; this was associated
with continued AHR expression, reinforc-
ing the parallels between IL-22-producing
ILC and Th22 cells (Colonna 2009). In the
absence of IL-1b, IL-22 and AHR expres-
sion from IL-15-stimulated IL-1R1hi stage
3 cells was lost. These results suggest
a critical role for IL-1b in regulating the
function of IL-22-producing ILCs,
although the results are also compatible
with overgrowth of a minor IL-1R1hi
subset lacking AHR and IL-22 expression.
IL-1bwas also able to influence the devel-
opment of classical NK cells from stage 3
cells. This effect was also restricted to the
IL-1R1hi subset and resulted in an overall
suppression of CD56 and CD94 expres-Immunitysion and a reduction in IFN-g production
and CD107a mobilization (a surrogate
marker for NK lytic granule exocytosis).
IL-1R1lo cells, in contrast, appeared as
precursors for classical NK cells. A clonal
analysis of IL-1R1hi and IL-1R1lo stage 3
cells were consistent with the observa-
tions made in bulk cultures; IL-1b sus-
tained IL-22 in IL-1R1hi cells while
reducing IL-15-dependent CD94 expres-
sion. These results suggest that IL-1b
could provide a molecular switch that
dictates development of IL-22-producing
ILCs versus classical NK cells from
common Id2-dependent precursors
(Figure 1).
Do the results of Hughes et al. distin-
guish the ‘‘dual function’’ from the ‘‘dual
precursor’’ model (Figure 1)? For the
moment, the jury is still deliberating.
Although IL-22 expression appears
restricted to the IL-1R1hi stage 3 subset,
this population is clearly heterogeneous
(for CD127, CD161, CD56, and NKp44)
providing ample opportunity for distinct
lineage-specific precursors of the dual
precursor model. Indeed, a recent report
showed that stage 3 iNK cells contain
a CD127+ cell subset with features of IL-
22 ILC, whereas the CD127 cell subset
contained precursors that could differen-
tiate into classical NK cells (Crellin et al.,
2010). In the mouse, fate-mapping exper-
iments have clearly shown that Rorc+
precursors of IL-22+ ILCs are distinct
from NK cell precursors for classical NK
cells (Satoh-Takayama et al., 2010), sup-
porting a dual precursor model in this
species. The observation by Hughes
et al. (2010) that IL-1b impacts on clas-
sical NK cell development in vitro would
appear to support the dual functionmodel
of a common IL-1R1hi precursor (Figure 1),
however, the existence of dedicated IL-
1R1hi subsets (CD127+ for IL-22+ ILC;
CD127- for NK cells) needs to be as-
sessed in clonal assays. Because NK22
and RORC+CD127+ cells retain some
phenotypic markers of classical NK cells,
analysis should include discriminating
markers (perforin, granzyme B) that are
only highly expressed by classical NK
cells.
Hughes et al. (2010) also identify
conventional DCs as a potential source
of IL-1b in SLT. This makes sense consid-
ering that cDCs are known to transpre-
sent IL-15-IL-15Ra complexes required
for homeostasis of NK cells (and perhaps32, June 25, 2010 ª2010 Elsevier Inc. 735
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Previewsother distinct ILCs). Because DCs also
produce key cytokines involved in the
process of T cell polarization (IL-12,
IL-18, and IL-23, for example), the prox-
imity of cDCs with IL-1R1hi stage cells
suggests a DC-controlled regulation of
ILC function within SLT and by analogy,
MALT. Along these lines, recent studies
have demonstrated extensive flexibility
of cytokine production by NK22 and
RORC+CD127+ cells after in vitro culture
with combinations of IL-1b, IL-2, IL-7, IL-
12, and/or IL-23 (Cella et al., 2010; Crellin
et al., 2010).
The identification by Hughes et al.
(2010) of an IL-1R1hi subset of IL-22-
producing innate lymphoid cells provides
another example of a DC ‘‘crosstalk’’736 Immunity 32, June 25, 2010 ª2010 Elsevwithin innate immune system. This DC-
ILC dialog may operate at multiple levels
to direct specific ILC subset development
as well as adapt ILC effector functions
during infection, inflammation, and tissue
regeneration.REFERENCES
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